EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+52.23%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$4.46B
AUM Growth
+$4.46B
(+49%)
Cap. Flow
+$210M
Cap. Flow
% of AUM
4.7%
Top 10 Holdings %
Top 10 Hldgs %
30.17%
Holding
145
New
24
Increased
36
Reduced
22
Closed
11
Top Buys
| 1 |
Pliant Therapeutics
PLRX
|
$88.4M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$42.5M |
| 3 |
Trane Technologies
TT
|
$40.2M |
| 4 |
Exact Sciences
EXAS
|
$30.3M |
| 5 |
Fiverr
FVRR
|
$29.4M |
Top Sells
| 1 |
Twilio
TWLO
|
$65.6M |
| 2 |
Xylem
XYL
|
$51.6M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$44M |
| 4 |
Varonis Systems
VRNS
|
$26.7M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$22.7M |
Sector Composition
| 1 | Healthcare | 46.53% |
| 2 | Technology | 23.12% |
| 3 | Industrials | 9.16% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Communication Services | 3.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLU
76
DELISTED
BELLUS Health Inc.
BLU
| $15.9M | 0.35% |
+1,543,000
| New | +$15.9M |
|
77
Sutro Biopharma
STRO
$85.6M
| $15.4M | 0.34% |
1,985,975
+700,000
| +54% | +$5.43M |
|
78
Immunovant
IMVT
$2.91B
| $15.2M | 0.33% |
+625,950
| New | +$15.2M |
|
79
Phathom Pharmaceuticals
PHAT
$843M
| $14.8M | 0.32% |
450,000
| – | – |
|
80
Repligen
RGEN
$6.54B
| $14.7M | 0.32% |
119,000
| – | – |
|
|
DCPH
81
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $14.5M | 0.32% |
243,000
| – | – |
|
82
Ciena
CIEN
$13.4B
| $14.5M | 0.31% |
+267,000
| New | +$14.5M |
|
83
Intuitive Surgical
ISRG
$158B
| $14.2M | 0.31% |
75,000
| – | – |
|
|
XLRN
84
DELISTED
Acceleron Pharma Inc.
XLRN
| $13.6M | 0.3% |
142,900
| – | – |
|
85
Lamb Weston
LW
$7.88B
| $13.3M | 0.29% |
208,600
-33,800
| -14% | -$2.16M |
|
86
Vertex Pharmaceuticals
VRTX
$102B
| $13.2M | 0.29% |
45,500
| – | – |
|
87
Immatics
IMTX
$662M
| $12.6M | 0.27% |
+800,000
| New | +$12.6M |
|
88
ESSA Pharma
EPIX
$11.2M
| $11.8M | 0.26% |
2,010,169
| – | – |
|
|
ALLK
89
DELISTED
Allakos
ALLK
| $11.5M | 0.25% |
160,000
| – | – |
|
90
89bio
ETNB
$1.37B
| $11.5M | 0.25% |
575,000
+225,000
| +64% | +$4.48M |
|
91
McCormick & Company Non-Voting
MKC
$18.7B
| $10.8M | 0.23% |
120,000
| – | – |
|
|
EIDX
92
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $10.2M | 0.22% |
213,000
| – | – |
|
|
CCXI
93
DELISTED
ChemoCentryx, Inc.
CCXI
| $10.1M | 0.22% |
+175,000
| New | +$10.1M |
|
94
Galapagos
GLPG
$2.06B
| $10.1M | 0.22% |
51,000
| – | – |
|
95
Xencor
XNCR
$594M
| $9.72M | 0.21% |
300,000
| – | – |
|
96
Fennec Pharmaceuticals
FENC
$247M
| $9.35M | 0.2% |
1,120,000
+400,000
| +56% | +$3.34M |
|
97
Arvinas
ARVN
$580M
| $7.71M | 0.17% |
230,000
| – | – |
|
98
Syndax Pharmaceuticals
SNDX
$1.39B
| $7.3M | 0.16% |
492,500
+265,820
| +117% | +$3.94M |
|
99
ADC Therapeutics
ADCT
$370M
| $7.02M | 0.15% |
+150,000
| New | +$7.02M |
|
100
Celldex Therapeutics
CLDX
$1.57B
| $6.02M | 0.13% |
+463,335
| New | +$6.02M |
|